Links to publications that use this product:
Chitravanshi et al. Bradycardia elicited by microinjections of nociceptin/orphanin FQ into the intermediolateral cell column at T1–T2 in the rat
Neurosci Lett. 2007 Apr 12;416(2):188-92.
Armstead. Differential activation of ERK, p38, and JNK MAPK by nociceptin/orphanin FQ in the potentiation of prostaglandin cerebrovasoconstriction after brain injury.
Eur J Pharmacol. 2006 Jan 4;529(1-3):129-35.
Chitravanshi et al. Mechanism of cardiovascular effects of nociceptin microinjected into the nucleus tractus solitarius of the rat.
Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1553-62.
Shah et al. Cardiovascular responses to microinjections of nociceptin into a midline area in the commissural subnucleus of the nucleus tractus solitarius of the rat.
Brain Res. 2003 Sep 12;984(1-2):93-103.
Muratani et al. Characterization of nociceptin/orphanin FQ-induced pain responses by the novel receptor antagonist N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide monohydrochloride.
J Pharmacol Exp Ther. 2002 Oct;303(1):424-30.
Zhao et al. Effect of orphanin FQ on interleukin-1beta mRNA transcripts in the rat CNS.
Neuroscience. 2002;114(4):1019-31.
Kapusta et al. Central administration of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)-NH2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats.
J Pharmacol Exp Ther. 1999 Apr;289(1):173-80.
Other Information:
Putative selective antagonist of the OFQ / Nociceptin receptor - Guerrini, R., et al., Bri. J. of Pharm. 123, 163-165 (1998)
For best results and reproducibility, rehydrate peptide just before use. Do not attempt to weigh out smaller portions. Do not refreeze any unused portions.